On Expert-Machine Partnership to Predict Mortality of Congestive Heart Failure Patients

This study examines the combined use of machine learning (ML) and expert judgment in predicting 30-day mortality for congestive heart failure (CHF) patients. It compares models using either expert-selected, ML-selected, or integrated features. The integrated model, merging expert and ML insights, outperforms others in predicting mortality risk, underscoring the value of combining human expertise and ML in clinical decision-making.</p

MOESM2 of Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial

Additional file 2: Table B. Baseline Clinical and Laboratory Characteristics of the study cohort by triglyceride level ≥ and < 200 mg/dl

MOESM1 of The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study

Additional file 1: Table S1. Showing the percentage change {Δ% = [(value after treatment - baseline value)/baseline value * 100]} in each group of patients after 12 weeks of treatment

Baseline characteristics and co-morbidities of the study population.

<p>Data are number (%) of patients or mean ± SD.</p><p>CRF - chronic renal failure, PVD - peripheral vascular disease.</p

Outcomes of the study population during follow-up (crude data).

<p>Data are number of events/(%).</p><p>- The primary endpoint of this study was 30-day Major Adverse Coronary Events (MACE): all-cause mortality, recurrent MI, recurrent ischemia, stent thrombosis, ischemic stroke, urgent revascularization during follow-up.</p

MOESM1 of Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease

Additional file 1: Table S1. Differences between the MetS definitions in terms of their individual components

Rate (%) of 30-day Major Adverse Coronary Events (MACE) among the study patients according to the age, gender, level of HDL cholesterol, triglycerides, smoking status, presence of diabetes and hypertension.

<p>Rate (%) of 30-day Major Adverse Coronary Events (MACE) among the study patients according to the age, gender, level of HDL cholesterol, triglycerides, smoking status, presence of diabetes and hypertension.</p

Effect of combined fibrate/statin treatment vs. statin monoterapy on 30-day Major Adverse Coronary Events (MACE) in risk subgroups: odds ratio and 95% confidence interval (CI).

<p>HDL-C - high density lipoproteins cholesterol.</p

Distribution of cardiovascular drugs among the study patients (on discharge).

<p>Distribution of cardiovascular drugs among the study patients (on discharge).</p

Kaplan-Meier curve of mortality rate during one year follow-up for 7243 patients from years 2000–2008 (combined fibrate/statin therapy vs. statin monotherapy, p log-rank = 0.066).

<p>Kaplan-Meier curve of mortality rate during one year follow-up for 7243 patients from years 2000–2008 (combined fibrate/statin therapy vs. statin monotherapy, p log-rank = 0.066).</p